Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Net Income (2016 - 2025)

Historic Net Income for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$34.9 million.

  • Sangamo Therapeutics' Net Income fell 42730.51% to -$34.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.9 million, marking a year-over-year increase of 1923.09%. This contributed to the annual value of -$97.9 million for FY2024, which is 6201.35% up from last year.
  • As of Q3 2025, Sangamo Therapeutics' Net Income stood at -$34.9 million, which was down 42730.51% from -$20.0 million recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Net Income ranged from a high of $21.1 million in Q1 2023 and a low of -$114.5 million during Q2 2023
  • Moreover, its 5-year median value for Net Income was -$44.0 million (2022), whereas its average is -$42.7 million.
  • In the last 5 years, Sangamo Therapeutics' Net Income tumbled by 306326.26% in 2021 and then skyrocketed by 14800.88% in 2023.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Net Income stood at -$37.5 million in 2021, then plummeted by 38.63% to -$51.9 million in 2022, then fell by 16.08% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
  • Its Net Income was -$34.9 million in Q3 2025, compared to -$20.0 million in Q2 2025 and -$30.6 million in Q1 2025.